MEPHOBARBITAL

MEPHOBARBITAL 구조식 이미지
카스 번호:
115-38-8
상품명:
MEPHOBARBITAL
동의어(영문):
Metyna;Mebaral;Meberal;Mephytal;Morbusan;Phemiton;Prominal;Enfenemal;Menta-bal;Phemetone
CBNumber:
CB2207809
분자식:
C13H14N2O3
포뮬러 무게:
246.26
MOL 파일:
115-38-8.mol

MEPHOBARBITAL 속성

녹는점
1760C
끓는 점
389.26°C (rough estimate)
밀도
1.1855 (rough estimate)
굴절률
1.6450 (estimate)
인화점
11 °C
저장 조건
Controlled Substance, -20°C Freezer
용해도
물에는 거의 녹지 않으며, 에탄올에는 아주 약간 녹습니다(96%).
산도 계수 (pKa)
7.99±0.10(Predicted)
물리적 상태
고체
물리적 상태
단단한 모양
색상
흰색에서 황백색까지
수용성
0.15g/L(20℃)
CAS 데이터베이스
115-38-8
EPA
2,4,6(1H,3H,5H)-Pyrimidinetrione, 5-ethyl-1-methyl-5-phenyl- (115-38-8)
안전
  • 위험 및 안전 성명
  • 위험 및 사전주의 사항 (GHS)
위험품 표기 Xn,T,F
위험 카페고리 넘버 22-39/23/24/25-23/24/25-11
안전지침서 36/37/39-45-36/37-16-7
유엔번호(UN No.) 3249
위험 등급 6.1(b)
포장분류 III
HS 번호 2933530000
유해 물질 데이터 115-38-8(Hazardous Substances Data)
독성 cat,LD50,oral,230mg/kg (230mg/kg),Drugs in Japan Vol. 6, Pg. 851, 1982.
그림문자(GHS): GHS hazard pictogramsGHS hazard pictogramsGHS hazard pictograms
신호 어: Danger
유해·위험 문구:
암호 유해·위험 문구 위험 등급 범주 신호 어 그림 문자 P- 코드
H225 고인화성 액체 및 증기 인화성 액체 구분 2 위험 GHS hazard pictograms P210,P233, P240, P241, P242, P243,P280, P303+ P361+P353, P370+P378,P403+P235, P501
H370 장기(또는, 영향을 받은 알려진 모든 장기를 명시)에 손상을 일으킴(노출되어도 특정 표적장기 독성을 일으키지 않는다는 결정적인 노출경로가 있다면 노출경로를 기재) 특정 표적장기 독성 - 1회 노출 구분 1 위험 GHS hazard pictograms P260, P264, P270, P307+P311, P321,P405, P501
예방조치문구:
P210 열·스파크·화염·고열로부터 멀리하시오 - 금연 하시오.
P280 보호장갑/보호의/보안경/안면보호구를 착용하시오.

MEPHOBARBITAL C화학적 특성, 용도, 생산

화학적 성질

White Crystalline Solid

용도

Controlled substance (depressant). Anticonvulsant; sedative; hypnotic

정의

ChEBI: A member of the class of barbiturates, the structure of which is that of barbituric acid substituted at N-1 by a methyl group and at C-5 by ethyl and phenyl groups.

일반 설명

Mephobarbital, 3-methyl-5-ethyl-5-phenylbarbituric acid (metharbital), is metabolicallyN-demethylated to phenobarbital, which many consider toaccount for almost all of the activity. Its principal use is asan anticonvulsant.

Clinical Use

Mephobarbital is a barbiturate-derivative AED with a pKa of 7.7 (log P = 1.84 at pH 7.4). Approximately 50% of an oral dose of mephobarbital is absorbed from the gastrointestinal tract. The plasma concentrations required for its therapeutic effects are unknown. The principal route of mephobarbital metabolism is N-demethylation by the liver to form phenobarbital, which may be excreted in the urine unchanged and as its p-hydroxy metabolite and glucuronide or sulfate conjugates. Conversion to the 4-hydroxy metabolite is stereoselective, being catalyzed by either CYP2C19 (R-enantiomer) or CYP2B6 (S-enantiomer); individuals who are CYP2C19 poor metabolizers show decreased clearance. Approximately 75% of a single oral dose of mephobarbital is converted to phenobarbital. It has not been determined whether mephobarbital contributes to the antiseizure effect or whether it results from its active metabolite, phenobarbital. Similarly, it is unclear whether mephobarbital, like phenobarbital, is a potent inducer of the enzymes involved in the metabolism of other drugs, but because the drug is chemically and pharmacologically similar to phenobarbital and is metabolized to phenobarbital, this possibility is likely.
Mephobarbital is less commonly used in the treatment of generalized and partial seizures. Like phenobarbital, it is classified as a long-acting barbiturate. No evidence exists that it is more effective than phenobarbital in equivalent doses; however, it may be less sedating in children.

Safety Profile

Poison by ingestion and intraperitoneal routes. A human teratogen by an unspecified route with developmental abnormalities of the cardovascular (circulatory) system. When heated to decomposition it emits toxic NOx. See also BARBITURATES.

MEPHOBARBITAL 준비 용품 및 원자재

원자재

준비 용품


MEPHOBARBITAL 관련 검색:

Copyright 2019 © ChemicalBook. All rights reserved